THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its subcutaneous (SC) formulation of TEPEZZA (teprotumumab-trbw). The data, released on April 6, 2026, indicates that the subcutaneous version—delivered via a convenient on-body injector—achieved efficacy levels nearly identical to the original intravenous (IV) treatment, potentially clearing the path for Amgen to transition its multibillion-party franchise from hospital-based infusions to home administration.

The results come at a critical juncture for the biotechnology giant as it seeks to fend off a wave of emerging competitors in the TED space. With a proptosis responder rate of 76.7% at Week 24, compared to just 19.6% for the placebo group, the subcutaneous formulation has not only met its primary endpoint but has also set a high efficacy bar that rivals have struggled to match. This development is expected to significantly lift Amgen’s medium-term revenue trajectory by extending the drug's lifecycle and expanding the accessible patient population.

Clinical Triumph: The TEPEZZA OBI Trial Results

The pivotal trial, known as the Phase 3 TEPEZZA OBI Trial (NCT06248619), was designed to evaluate the safety and efficacy of the subcutaneous delivery system. The study utilized an innovative on-body injector (OBI), designed to make the administration process far less burdensome than the current IV infusion, which typically requires hours in a clinic. Beyond the primary endpoint of proptosis reduction (bulging of the eyes), the trial met all key secondary endpoints, including improvements in double vision (diplopia) and the Clinical Activity Score (CAS).

This achievement is the culmination of years of development that began prior to Amgen's $27.8 billion acquisition of Horizon Therapeutics. Since the acquisition closed, Amgen has prioritized the "subcu" formulation as a defensive and offensive strategic asset. The safety profile observed in the SC trial was consistent with previous IV studies, showing typical side effects like muscle spasms and hearing changes, but with the added benefit of only mild-to-moderate injection site reactions. The market reacted with immediate optimism, as analysts noted that maintaining "IV-level efficacy" in a subcutaneous shot is a rare and difficult clinical feat.

Winners and Losers in the TED Landscape

While Amgen (NASDAQ: AMGN) celebrates a victory, the landscape for its competitors has grown considerably more treacherous. Viridian Therapeutics (NASDAQ: VRDN) had been positioned as the primary challenger with its own SC candidate, elegrobart (VRDN-003). However, recent Phase 3 data for elegrobart showed a proptosis responder rate in the 54% to 63% range. While statistically significant, these numbers trail Amgen's 77% result, leading many investors to fear that Viridian may only capture the "low-hanging fruit" of the market rather than challenging Amgen for the top spot. Viridian’s stock saw a sharp decline following the comparison of the two datasets.

The news was even more somber for Immunovant (NASDAQ: IMVT). Just as Amgen was highlighting its success, Immunovant reported that its lead candidate for TED, batoclimab, failed to meet the primary endpoint in two separate Phase 3 "GO" studies. The failure has effectively eliminated batoclimab from the TED race, forcing the company to pivot entirely to its next-generation asset, IMVT-1402. For now, the "winner" circle is occupied almost exclusively by Amgen, which has effectively built a "fortress" around its TED franchise, leaving rivals to fight for smaller niches or hope for breakthroughs in secondary mechanisms.

Broader Industry Trends and the SC Revolution

The shift from IV to SC administration is a broader trend within the biotechnology industry, as companies look to improve patient adherence and lower healthcare costs by moving treatments out of the infusion center and into the home. For Amgen, the SC TEPEZZA success is a masterclass in lifecycle management. By introducing a more convenient delivery method, the company creates a "sticky" patient base that is less likely to switch to generic or biosimilar alternatives once they eventually enter the market.

Furthermore, this event highlights the high failure rate in the TED space for non-IGF-1R mechanisms. The failure of Immunovant’s FcRn inhibitor suggests that the IGF-1R pathway, which TEPEZZA targets, remains the undisputed gold standard for treating the underlying causes of TED. Regulatory bodies like the FDA are increasingly looking for these types of "patient-centric" innovations—treatments that offer the same clinical benefit but with significantly reduced logistical burdens on the patient and the healthcare system.

The Road Ahead: Regulatory Catalysts and Market Expansion

Amgen is now moving at full speed toward a supplemental Biologics License Application (sBLA) filing, with expectations that the SC TEPEZZA could reach the market by late 2026 or early 2027. The next six months will be pivotal as the company prepares its manufacturing and commercial infrastructure for a widespread rollout of the on-body injector. Investors are also keeping a close eye on the June 30, 2026, PDUFA date for Viridian’s IV product, which will be the first real test of price competition in a market that Amgen has owned since 2020.

Long-term, the success of the SC formulation allows Amgen to target patients with milder forms of TED who may have been reluctant to undergo the rigors of IV therapy. This expansion of the "total addressable market" is a key reason why analysts have revised their revenue forecasts upward. If Amgen can successfully convert the majority of its IV users to the SC version before more competitors arrive, it will have secured a multi-billion dollar revenue stream well into the 2030s.

Summary of the Market Impact

The positive Phase 3 data for subcutaneous TEPEZZA marks a definitive moment for Amgen and the thyroid eye disease community. By delivering high-impact efficacy through a more convenient delivery system, Amgen has effectively neutralized much of the competitive threat posed by late-stage rivals. The failure of competing mechanisms like batoclimab only serves to reinforce the dominance of the IGF-1R inhibitor class.

Moving forward, the market will focus on Amgen’s ability to execute this commercial transition. Investors should watch for the sBLA filing timeline and any signals from payers regarding the pricing of the SC formulation versus the IV version. While challenges remain—including potential price pressure from Viridian—Amgen’s "TED fortress" looks more secure today than it has in years. The combination of clinical excellence and strategic foresight has positioned the company to remain the undisputed leader in this high-value therapeutic area.

This content is intended for informational purposes only and is not financial advice.